HUP0100241A2 - Eljárás gyulladásos betegségek hősokk-proteinek alkalmazásával történő kezelésére - Google Patents

Eljárás gyulladásos betegségek hősokk-proteinek alkalmazásával történő kezelésére Download PDF

Info

Publication number
HUP0100241A2
HUP0100241A2 HU0100241A HUP0100241A HUP0100241A2 HU P0100241 A2 HUP0100241 A2 HU P0100241A2 HU 0100241 A HU0100241 A HU 0100241A HU P0100241 A HUP0100241 A HU P0100241A HU P0100241 A2 HUP0100241 A2 HU P0100241A2
Authority
HU
Hungary
Prior art keywords
heat shock
shock protein
mammal
disease
hsp
Prior art date
Application number
HU0100241A
Other languages
English (en)
Hungarian (hu)
Inventor
Erwin W. Gelfand
Angela Francisca Haczku
Katalin Veronika Lukacs
Original Assignee
National Jewish Medical And Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Jewish Medical And Research Center filed Critical National Jewish Medical And Research Center
Publication of HUP0100241A2 publication Critical patent/HUP0100241A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU0100241A 1998-01-23 1999-01-22 Eljárás gyulladásos betegségek hősokk-proteinek alkalmazásával történő kezelésére HUP0100241A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1233098A 1998-01-23 1998-01-23
PCT/US1999/001421 WO1999037319A1 (en) 1998-01-23 1999-01-22 Method for treating inflammatory diseases using heat shock proteins

Publications (1)

Publication Number Publication Date
HUP0100241A2 true HUP0100241A2 (hu) 2001-06-28

Family

ID=21754459

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100241A HUP0100241A2 (hu) 1998-01-23 1999-01-22 Eljárás gyulladásos betegségek hősokk-proteinek alkalmazásával történő kezelésére

Country Status (16)

Country Link
US (2) US20020006410A1 (https=)
EP (1) EP1049483A1 (https=)
JP (1) JP2002509074A (https=)
KR (1) KR20010040389A (https=)
CN (1) CN1324243A (https=)
AU (1) AU2337499A (https=)
BR (1) BR9907228A (https=)
CA (1) CA2318263A1 (https=)
CZ (1) CZ20002669A3 (https=)
HU (1) HUP0100241A2 (https=)
IL (1) IL137404A0 (https=)
NO (1) NO20003775L (https=)
PL (1) PL342166A1 (https=)
TR (1) TR200002973T2 (https=)
WO (1) WO1999037319A1 (https=)
ZA (1) ZA99499B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7992572B2 (en) * 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
US6638518B1 (en) * 1999-02-22 2003-10-28 University Of Iowa Research Foundation Method for inhibiting inflammatory responses
WO2001022816A1 (en) * 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
EP1551957A4 (en) * 2001-10-01 2007-01-24 Univ Duke ISOLATED POLYPEPTIDE OF THE GRP94 LIGANDEN BINDING DOMAIN AND NUCLEIC ACID, CRYSTALLINE FORM THEREOF, CODING THEREOF, AND SCRAPPING METHOD WHERE IT IS USED
US20030216315A1 (en) * 2002-02-13 2003-11-20 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
KR100615389B1 (ko) * 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
US20100111927A1 (en) * 2002-08-23 2010-05-06 Sunyoung Kim Compositions Comprising Actinidia and Methods of Use Thereof
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
JP2009511610A (ja) * 2005-10-20 2009-03-19 シービーアイオー リミテッド 過敏症治療
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
US8540985B2 (en) 2008-06-26 2013-09-24 Orphazyme Aps Use of Hsp70 as a regulator of enzymatic activity
WO2010086418A1 (en) * 2009-01-29 2010-08-05 Alfa Biogene International B.V. Functional food product comprising heat shock protein or a hydrolysate thereof
EP2397074B1 (en) * 2010-06-19 2012-10-24 M Stenqvist AB A system and computer readable medium for determination of transpulmonary pressure in a patient connected to a breathing apparatus
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
WO2012097255A2 (en) * 2011-01-14 2012-07-19 Scott & White Healthcare Therapeutic effect of heat shock proteins in preventing amylin aggregation in type 2 diabetes mellitus
HUE044867T2 (hu) 2011-05-12 2019-11-28 Proteostasis Therapeutics Inc Proteosztázis szabályzók
US20140228315A1 (en) * 2011-06-16 2014-08-14 Children's Hospital Medical Center Blockade of eosinophil production by toll-like receptors
US10034915B2 (en) 2011-06-23 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
EP2806875B1 (en) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
WO2017123401A1 (en) 2016-01-13 2017-07-20 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
KR20210059796A (ko) 2016-04-29 2021-05-25 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
CN106243203B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP70及其应用
CN106220718B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP60及其应用
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
JP7561632B2 (ja) 2018-06-27 2024-10-04 キネタ， インコーポレイテッド プロテアソーム活性増強化合物
WO2020006269A1 (en) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
CN114046596B (zh) * 2021-11-17 2022-09-23 重庆大学 基于trp生化指标检测的室内空气质量控制系统及方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
ATE154759T1 (de) * 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
GB9211736D0 (en) * 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
JP4484969B2 (ja) * 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答

Also Published As

Publication number Publication date
ZA99499B (en) 1999-07-22
EP1049483A1 (en) 2000-11-08
KR20010040389A (ko) 2001-05-15
CN1324243A (zh) 2001-11-28
CA2318263A1 (en) 1999-07-29
TR200002973T2 (tr) 2001-02-21
PL342166A1 (en) 2001-05-21
US20020006410A1 (en) 2002-01-17
IL137404A0 (en) 2001-07-24
BR9907228A (pt) 2000-10-24
CZ20002669A3 (cs) 2001-11-14
WO1999037319A1 (en) 1999-07-29
NO20003775D0 (no) 2000-07-21
US20070179087A1 (en) 2007-08-02
JP2002509074A (ja) 2002-03-26
AU2337499A (en) 1999-08-09
NO20003775L (no) 2000-09-22

Similar Documents

Publication Publication Date Title
HUP0100241A2 (hu) Eljárás gyulladásos betegségek hősokk-proteinek alkalmazásával történő kezelésére
US5906815A (en) Treatment for diseases involving inflammation
Smaldone Repurposing of gamma interferon via inhalation delivery
Rha et al. Effect of microbial heat shock proteins on airway inflammation and hyperresponsiveness
KR101908445B1 (ko) 변형된 면역-조절 입자
CN1498108A (zh) 用于治疗炎性疾病的烟碱性受体激动剂
US6248723B1 (en) Method for treatment of inflammatory disease
CN111867565A (zh) 使用耐受颗粒治疗乳糜泻
US20070065367A1 (en) Method of treating pulmonary disease with interferons
US20180155435A1 (en) Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
US20020141995A1 (en) Method for treatment of inflammatory disease
WO2023009567A1 (en) Compositons and methods for the treatment of bronchopulmonary dysplasia (bpd) and bpd-associated pulmonary hypertension
MXPA00007148A (es) Metodo para el tratamiento de enfermedades inflamatorias usando proteinas de choque termico
JP2005508906A (ja) 抗炎症剤
CA2622987C (en) Method of treating pulmonary disease with interferons
US8105571B2 (en) Method of treating pulmonary disease with interferons
US20220273768A1 (en) Intranasal leptin compositions and methods of use thereof for prevention of opioid induced respiratory depression in obesity
KR20100123240A (ko) 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
JPWO2003020306A1 (ja) 脱感作剤
DE102005049800A1 (de) Verfahren zur Auffindung von Inhibitoren des Epstein-Barr-Virus-induzierten Gens 3 (EBI 3) und deren Verwendungen bei der Behandlung von metastasierenden Tumoren und allergischem Asthma
RU2587853C2 (ru) Модифицированные иммуномодулирующие частицы
CN115397433A (zh) 含有海藻糖或海藻糖衍生物的药物和鼻喷雾剂
WO2025231092A1 (en) Compositions and methods for the stimulation of intermediate macrophages and treatments therewith
CN118043055A (zh) 用于治疗支气管肺发育不良（bpd）和bpd相关肺动脉高血压的组合物和方法
AU2007237181A1 (en) Small peptides and methods for downregulation of IgE